RCKT · Rocket Pharmaceuticals, Inc. · Investor Relations

CRANBURY, N.J. --(BUSINESS WIRE)--Oct. 15, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that the

CRANBURY, N.J. --(BUSINESS WIRE)--Oct. 7, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its

CRANBURY, N.J. --(BUSINESS WIRE)--Oct. 6, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has

FDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol FDA review of initial safety data supports continued enrollment and dosing under modified protocol FDA confirms established 12-month co-primary endpoints intended to support

CRANBURY, N.J. --(BUSINESS WIRE)--Sep. 3, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced that the Company

All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic microangiopathy, capillary leak syndrome, or other significant safety concerns observed Rocket is actively engaging with the FDA to

Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observed Rocket is actively engaging with the FDA to align on the path to pivotal trial completion; regulatory pathway update expected in the second half of 2026 Comprehensive Danon disease

CRANBURY, N.J. --(BUSINESS WIRE)--Jun. 12, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the closing of the sale of its

CRANBURY, N.J. --(BUSINESS WIRE)--May 28, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate

Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 KRESLADI™ granted FDA accelerated approval; Rare Pediatric Disease Priority Review Voucher

PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline Cash runway extended into the second quarter of 2028 CRANBURY, N.J. --(BUSINESS WIRE)--Apr. 28, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology

First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections and high early-childhood mortality without treatment FDA grants Rare Pediatric

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI ™ for severe LAD-I on track for March 28, 2026 PDUFA date Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 Cash, cash equivalents and investments of

CRANBURY, N.J. --(BUSINESS WIRE)--Feb. 23, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the

CRANBURY, N.J. --(BUSINESS WIRE)--Jan. 5, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the

CRANBURY, N.J. --(BUSINESS WIRE)--Nov. 25, 2025-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date Leadership updates with the appointments of Dr. Syed Rizvi , Chief Medical Officer, Christopher Stevens , Chief Operating Officer, and Sarbani Chaudhuri , Chief